Myllia Biotechnology

Myllia Biotechnology is a Vienna-based, private biotech leveraging a proprietary functional genomics platform that integrates pooled CRISPR screening (CRISPRn/i/a) with single-cell RNA sequencing (CROP-seq) in primary human immune cells. This approach enables unbiased, causal target discovery and mechanism-resolved validation, positioning the company as a partner for pharma and biotech in oncology and autoimmunity. Myllia also generates rich, AI-ready perturbation datasets to train foundation models of cell biology. The company is pre-revenue, operating as a platform and services provider to de-risk early-stage drug discovery for clients.

Integrated platform combining pooled CRISPR screening (CRISPRn/i/a) with single-cell RNA sequencing (CROP-seq) in primary human cells (e.g., immune cells) for high-content, mechanism-resolved target discovery and AI/ML-ready dataset generation.

Myllia competes with large CROs offering genomic services, specialized functional genomics startups, and academic core facilities. Its key differentiator is the focus on primary human cell models combined with single-cell readouts, aiming for higher physiological relevance and deeper mechanistic insight than standard cell-line-based screens.